Successful trials for treatment of gastric infections

Israel’s Redhill Biopharma announced positive top-line results from its Phase III study with RHB-105 for treating Helicobacter pylori (H. pylori) infections. RHB-105 achieved 89.4% efficacy in eradicating H. pylori with no serious adverse events or unexpected safety issues.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *